Last reviewed · How we verify
Standard Dose Inactivated Influenza Vaccine
The Standard Dose Inactivated Influenza Vaccine, developed by the University of Pittsburgh, is a marketed product with a key composition patent expiring in 2028. The vaccine's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition as the patent approaches expiration in 2028.
At a glance
| Generic name | Standard Dose Inactivated Influenza Vaccine |
|---|---|
| Sponsor | University of Pittsburgh |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: